Provider review
Transcend Company Review: One Site, Two Registers, and an Empty Science Page
Transcend is in the middle of rewriting itself and has left both drafts live. On /pages/weight-loss, tesofensine is "currently being studied for its potential effects on appetite regulation" and the page states twice that "Compounded drug products are not FDA-approved. FDA does not evaluate compounded products for safety, effectiveness, or quality" — which is the sentence this site exists to ask for. One click away, /pages/semaglutide still describes "Peptides like semaglutide, tirzepatide, and tesofensine", and tesofensine is not a peptide. /pages/tesamorelin says the molecule "has FDA approval for targeted fat reduction and metabolic improvement" with the actual indication — HIV-associated lipodystrophy — removed. Six more programmes are sold as peptide "stacks" and "trios" with no molecule named at all. The pages that would explain who prescribes and on what basis — "The Science", "Our Team", "eūvita Medical" — are published, in the sitemap, and blank.
Compounded only
Phase 3 trials
Named
None found
Disclosure: Some links on this site are affiliate or referral links. If you start a treatment or buy a product through them, we may earn a commission at no additional cost to you. Read our full disclosure.
Opens transcendcompany.com. A link is not a recommendation to take anything.
Provenance
What Transcend actually dispenses
Regulatory category is the axis consumers are most reliably misled about, so it comes first. Every product below is sorted by what it legally is, not by what it costs.
Prepared by a state-licensed pharmacy against a prescription for a named patient. Compounded preparations are not FDA-approved and are not reviewed by FDA for safety, effectiveness or quality.
- Tesamorelin — Not published. The storefront's public product endpoint returns eight items — lab panels and supplements — and the only purchasable clinical entry point is a $199 "Fast Track Starter Package with Guided Care" covering lab work and a wellness consultation. No figure for tesamorelin, or for any medication, appears on any of the 60 pages.
- Tesofensine (offered within the weight-loss programme)
- Semaglutide (GLP-1) weight-loss programme — Not published. No medication price appears anywhere on the site; the storefront sells lab panels, supplements and a $199 starter package, and the site states that Transcend "does not work with health insurers, but we do accept HSA and FSA as a method of payment."
- GHK-Cu, within the skin-and-hair peptide programme
- Epitalon, within the skin-and-hair peptide programme
- Cognitive Clarity stack
Evidence
Is there a human trial at all?
One row per product, graded on how far the published human evidence goes for the use it is sold for — not for the molecule in general. A molecule with phase 3 evidence for one outcome has none for another, and that distinction is where peptide marketing lives.
4
Products with a human trial
Out of 6 reviewed here.
9
Registry records cited
Each read live from ClinicalTrials.gov, never from memory.
The comparison
What they claim, against what the trials show
Each claim below is quoted verbatim from Transcend’s own page, with the page it came from. Grading a paraphrase would prove nothing. Every row is the verdict at a glance — tap it to open the quote, the trial registry entries, and the full note behind that verdict.
TesamorelinTesamorelin · Compounded (503A)Claim reaches past the trials
“Tesamorelin is a prescription peptide that helps your body reignite its natural growth hormone production—so you perform, look, and feel the way you used to. Start seeing sleep, recovery and energy improvements in the first 2-4 weeks, with total body composition changes in just 8-12 weeks… Tesamorelin was developed through years of clinical research and has FDA approval for targeted fat reduction and metabolic improvement, with over a decade of data showing improved metabolism, body composition, and insulin sensitivity… Key Benefits: Enhanced Growth Hormone Production · Visceral Fat Reduction · Improved Sleep Quality · Cardiovascular Health · Triglyceride Reduction · Cognitive Enhancement · Faster Recovery · Lean Muscle Gain.”
Phase 3 trials
- NCT00123253 — Phase 3, completed, n=412. Sponsor Theratechnologies. "A Phase 3 Multicenter, Double-Blind, Randomized, Placebo-Controlled Study Assessing the Efficacy and Safety of a 2 mg Dose of TH9507… in HIV Patients With Excess of Abdominal Fat Accumulation." Conditions: HIV infections, lipodystrophy. Ran June 2005 to April 2007.
- NCT00675506 — Phase 2, completed, n=60. Massachusetts General Hospital, "Physiologic Effects of Long-Term GHRH1-44 in Abdominal Obesity" — the only registered study of the molecule in abdominal obesity outside HIV. Completed January 2012.
- NCT02553603 — Phase 1, completed, n=22. University of Texas Medical Branch, Galveston. "The Effect of Growth Hormone Releasing Hormone on Cognitive Function in Individuals With Mild Cognitive Impairment." Phase 1, 22 participants, completed January 2019. This and one 151-participant phase 2 at the University of Washington are the registered basis for any cognition claim; neither studied healthy adults seeking enhancement.
"Has FDA approval for targeted fat reduction and metabolic improvement" is the approved indication with the patients deleted. The label reads: "EGRIFTA WR is indicated for the reduction of excess abdominal fat in HIV-infected adult patients with lipodystrophy", and under Limitations of Use, "EGRIFTA WR is not indicated for weight loss management as it has a weight neutral effect." There is no approval for "metabolic improvement" of any kind. The approval also belongs to a specific finished product; Transcend's four named pharmacies are compounders, and the site's own weight-loss page states that "Compounded drug products are not FDA-approved" — a sentence that, applied here, contradicts the tesamorelin page directly. Of the eight bulleted key benefits, one is the trial's own result: visceral fat reduction, in HIV-associated lipodystrophy, in a 412-patient phase 3 where CT-measured visceral adipose tissue fell 15.2% against a 5.0% rise on placebo. "Cognitive Enhancement" rests on trials in mild cognitive impairment, not on healthy adults. "Lean Muscle Gain" is what Limitations of Use is about. And "total body composition changes in just 8-12 weeks" is a timeline no registered trial of this molecule reports for the population being sold to.1,2,3,4,5
Tesofensine (offered within the weight-loss programme)Tesofensine · Compounded (503A)No trial supports this claim
“Peptides like semaglutide, tirzepatide, and tesofensine have shown potential in aiding weight loss… Tesofensine is another peptide that works as a triple monoamine reuptake inhibitor. It enhances the levels of serotonin, dopamine, and norepinephrine in the brain, which can suppress appetite and promote weight loss.”
Phase 2 only
- NCT00394667 — Phase 2, completed, n=200. Sponsor NeuroSearch A/S. "Effect of Tesofensine on Weight Reduction in Patients With Obesity. A Randomized, Double-blind, Placebo-controlled, Parallel-group, Multi-centre Study." Enrolment 200 estimated; ran September 2006 to September 2007. This is the largest registered obesity trial of the molecule.
- NCT00481104 — Phase 2, completed, n=140. NeuroSearch A/S, long-term safety of tesofensine in obesity, 140 participants.
- NCT02737891 — Phase 2, completed, n=60. Saniona, tesofensine/metoprolol ("Tesomet") in hypothalamic obesity, 60 participants. Across all 13 registered tesofensine studies the highest phase reached is 2; there is no registered phase 3 of tesofensine for any indication.
Two problems, and the first is a category error a peptide site cannot let pass. Tesofensine is not a peptide. It is a small-molecule triple monoamine reuptake inhibitor — the page says so in the same sentence in which it calls it a peptide, because "works as a triple monoamine reuptake inhibitor" is a description of a small molecule and not of a signalling peptide. It began life as NS 2330, a Boehringer Ingelheim candidate for Parkinson's disease and Alzheimer's disease. The second is the evidence: thirteen tesofensine studies are registered and not one reaches phase 3. The largest obesity trial is 200 participants, phase 2, completed in 2007; no product containing tesofensine has an FDA approval, and a DailyMed query returns zero labels. Selling it as one of three "peptides" alongside semaglutide and tirzepatide places an unapproved phase-2 molecule beside two with completed phase 3 programmes and asks the reader to treat them as the same class of thing. Transcend's own /pages/weight-loss has already been rewritten to say only that "Tesofensine is currently being studied for its potential effects on appetite regulation" — the honest version exists on the same site.6,7,8
Semaglutide (GLP-1) weight-loss programmeSemaglutide · Compounded (503A)Claim matches the trials
“Semaglutide is a peptide that acts as a glucagon-like peptide-1 (GLP-1) receptor agonist. It helps reduce appetite and increase feelings of fullness, leading to reduced food intake and weight loss… Tirzepatide, a groundbreaking once-weekly injectable peptide, takes center stage as a dual GIP and GLP-1 receptor agonist. Approved for its remarkable ability to promote substantial weight loss… Compounded drug products are not FDA-approved. FDA does not evaluate compounded products for safety, effectiveness, or quality. Prescription products require an online consultation with a healthcare provider who will determine if a prescription is appropriate.”
Phase 3 trials
- NCT03548935 STEP 1 — Phase 3, completed, n=1,961. Novo Nordisk. Once-weekly semaglutide 2.4 mg versus placebo in adults with overweight or obesity, 68 weeks, 1,961 participants. The trial drug was the approved finished product; no compounded semaglutide from any seller has been through a registered trial.
- NCT04184622 SURMOUNT-1 — Phase 3, completed, n=2,539. Eli Lilly. Once-weekly tirzepatide versus placebo in adults with obesity or overweight with weight-related comorbidities, 2,539 participants, completed 6 July 2024.
The mechanism sentences are accurate and unembellished — no percentage is quoted, no timeline is promised, and the description of what a GLP-1 receptor agonist does to appetite and satiety is the trials' own. Tirzepatide is correctly described as a dual GIP and GLP-1 receptor agonist and as approved for weight management. What lifts this row above the rest of the site is the paragraph underneath, printed twice on the same page: "Compounded drug products are not FDA-approved. FDA does not evaluate compounded products for safety, effectiveness, or quality." That is the compounded-is-not-the-trial-drug distinction, volunteered by the seller, on the page where it matters. The remaining gap is that the distinction is drawn only here: the tesamorelin page, which sells a compounded copy of an approved drug, carries no such line and instead borrows the approval outright.9,10,11,12
GHK-Cu, within the skin-and-hair peptide programmeGHK-Cu · Compounded (503A)Claim reaches past the trials
“GHK-Cu is a copper-binding peptide studied for its potential role in signaling pathways associated with collagen and skin structure… Our programs focus on supporting wellness factors connected to: Collagen signaling pathways · Metabolic balance · Cellular repair processes · Overall recovery and vitality.”
Phase 2 only
- NCT07437586 — Phase 2, recruiting, n=60. Sponsor Hudson Biotech. "A Phase 2, Randomized, Double-Blind, Vehicle-Controlled, Split-Wound Study of Topical GHK-Cu (Copper(II)-Peptide Complex) Gel to Accelerate Re-Epithelialization of Standardized Acute Skin Wounds in Healthy Adults." Started 2 February 2026, estimated completion 17 March 2028, target 60. The only registered trial of GHK-Cu as an intervention; it is TOPICAL, it is recruiting, and it has reported nothing.
The sentence itself is carefully built to be unfalsifiable — "studied for its potential role in signaling pathways" asserts that research exists, not that a result does, and research does exist. What reaches past the evidence is the placement: the molecule appears under the heading "How Peptide and Hormone Therapy Works for Better Skin and Hair", inside a programme a customer is invited to buy. The registry holds exactly one GHK-Cu intervention trial, it opened for recruitment in February 2026, it will not report before 2028, and it studies a TOPICAL gel on punch-biopsy wounds — not a systemic programme for skin appearance. FDA separately names "GHK-Cu (for injectable routes of administration)" on its published page of bulk drug substances that may present significant safety risks, stating that compounded injectable drugs containing it "may pose risk for immunogenicity due to the potential for aggregation and peptide-related impurities". The page does not say which route Transcend dispenses.1,13
Epitalon, within the skin-and-hair peptide programmeEpitalon (epithalon) · Compounded (503A)Claim reaches past the trials
“Epitalon has been investigated in longevity research related to cellular aging pathways.”
No human trial
As of 9 August 2026, a ClinicalTrials.gov v2 intervention search returned ZERO studies for "epitalon", zero for the alternative spelling "epithalon" and zero for "epithalamin". No registered trial of this molecule exists anywhere in the registry, for any indication, under any spelling. A DailyMed query for epitalon returns zero labels. The randomised literature that a looser search surfaces tests EPITHALAMIN — a peptide extract of bovine pineal gland, not the synthetic tetrapeptide — and comes from a single research group.
"Has been investigated in longevity research related to cellular aging pathways" is true of the laboratory literature and is doing a great deal of work on a page that offers the molecule as part of a purchasable programme. There is no registered human trial of epitalon anywhere, under any spelling, for any indication — so "investigated" here means cell and animal work plus a small unregistered literature about a different substance, the bovine pineal extract epithalamin. Two things follow. A reader who takes "investigated in longevity research" to mean "tested in people" has been misled by a sentence that never technically says so. And FDA names epitalon on its published page of bulk drug substances that may present significant safety risks, stating that it "has not identified safety-related information regarding epitalon for the proposed route of administration" — the agency's way of saying it does not know.1,14
Cognitive Clarity stackNot named — sold as "three physician-prescribed neuropeptides" · Compounded (503A)No trial supports this claim
“The Cognitive Clarity stack combines three physician-prescribed neuropeptides that work together to support memory, focus, mood stability and long-term performance… Clarity: Quiet mental noise so you can stay present & productive. Cognition: Enhance recall, learning and idea flow. Confidence: Perform under stress without the crash.”
No human trial
No registry record can be matched to this claim, because Transcend names no molecule for it. All 60 pages in the published pages sitemap were downloaded on 9 August 2026 (26 MB) and searched: the strings "BPC-157", "BPC 157", "TB-500", "CJC-1295", "sermorelin" and "ipamorelin" occur ZERO times across the whole site, and the only molecules named anywhere are tesamorelin, semaglutide, tirzepatide, tesofensine, GHK-Cu and epitalon. None of those six is a nootropic. As a bound on the class this stack describes, the two molecules this market usually reaches for are semax and selank; a PubMed search restricted to the randomised-controlled-trial publication type returns three records for the pair, all published in the Russian-language journal Zhurnal Nevrologii i Psikhiatrii between 2007 and 2015, and FDA names both "semax (heptapeptide)" and "selank acetate (TP-7)" on its page of bulk substances that may present significant safety risks.
"Enhance recall, learning and idea flow" and "perform under stress without the crash" are cognitive-performance claims stated flatly, with no molecule attached to any of them. That is not a rhetorical complaint: a drug that is not named cannot be looked up, cannot be checked for interactions, cannot be checked against a trial, and cannot be checked against FDA's list of bulk substances a pharmacy may not lawfully compound from. The same pattern covers Healing & Recovery ("an advanced peptide and cartilage-support trio"), Immune Resilience ("one of the most synergistic immune optimization trios available in clinical peptide and cellular medicine"), Skin Care, Men's Sexual Wellness and the Men's Vitality Bundle. Six programmes, all sold by outcome, none by molecule.1,15
Dispensing chain
Who actually fills your prescription
- AnazaoHealth — 5710 Hoover Boulevard, Tampa, FL 33634, (800) 995-4363
- Tailor Made Compounding — 200 Moore Dr., Nicholasville, KY 40356, (859) 887-0013
- Vios Compounding — 31035 Schoolcraft Rd., Livonia, MI 48150, (800) 518-9831
- Brooksville Rx — 16140 Flight Path Dr., Brooksville, FL, (352) 848-3446
Read the full account
Transcend names its pharmacies, and it is the strongest structural disclosure on the site. The terms of conditions, effective 7 January 2026, state that "Our Service provides access to prescription fulfillment services offered by pharmacies (the 'Pharmacies')… You agree and understand that your prescription(s) may be filled by and transferred between any of the Pharmacies, and agree that the Service may do so on your behalf", and then list four with street addresses and telephone numbers. The same document separates the corporate layer from the clinical one: "We may also provide you with access to one or more medical groups who provide healthcare services through the Platform. These medical groups employ or contract with physicians and allied health professionals… We do not control or interfere with the practice of medicine", and "Transcend is not a healthcare provider". What it does not do is describe the regulatory category of anything it sells. Across all 60 pages the strings "503A" and "503B" occur ZERO times, and the phrase "compounding pharmacy" occurs zero times — the word "Compounding" appears on the site only as part of two pharmacies' company names. The single place the category is stated is /pages/weight-loss, twice: "Compounded drug products are not FDA-approved. FDA does not evaluate compounded products for safety, effectiveness, or quality." That sentence is correct, it is volunteered, and it is confined to one page — which is why the tesamorelin page can say the molecule "has FDA approval" without any adjacent line reminding a reader that a compounded copy does not inherit one. On the pharmacies themselves: AnazaoHealth Corporation received an FDA warning letter dated 18 August 2021 concerning a facility registered as an outsourcing facility under section 503B, but that letter is addressed to 7465 W. Sunset Road, Suite 1200, Las Vegas, NV 89113 — a different site from the Tampa address Transcend prints — so it is reported here as the same corporation at a different registered facility and is not attributed to the pharmacy named. Tailor Made Compounding, Vios Compounding and Brooksville Rx each returned recordsFiltered=0 on the identical query shape. A page titled "eūvita Medical", which the sitemap suggests is the affiliated medical group, is published and blank.
Read on August 2026 from https://transcendcompany.com/pages/terms-and-conditions
Quality
Third-party testing, and what is published
Describes a testing regime
Nothing published on the pages searched
Certificate of analysis readable
No lot report a buyer can open
Read the full testing account
Transcend describes no testing regime for any compounded product, and unusually it does not claim one either. All 60 pages were downloaded on 9 August 2026 and searched: "certificate of analysis", "third-party tested", "third party tested", "sterile", "potency", "purity" and "tested for" each occur ZERO times, and "USP" as a standard occurs zero times (the only match in the corpus is the substring inside another word). There is no purity badge, no laboratory named, no testing frequency, and no lot report — but there is also no unsupported assertion that testing happens, which is a different failure mode from the industry norm and marginally the better one: nothing here has to be discounted. The closest the site comes to a quality statement is the disclaimer on /pages/weight-loss that "FDA does not evaluate compounded products for safety, effectiveness, or quality", which is a statement about what nobody has checked rather than a claim about what Transcend has. Extensive lab TESTING of the customer is described in detail — a comprehensive panel through Quest, results in 7 to 10 business days, delivered to a Quest patient portal — but that is diagnostics, not product testing, and the two are easy to confuse on a site that uses the word "testing" mostly for the first.
Read on August 2026 from https://transcendcompany.com/pages/weight-loss
Licensing
Licensed to dispense, and where
Coverage
All 50 states and the District of Columbia, per the provider's own FAQ; 18+, or 21+ for some services
Read the full licensing claim
The FAQ answers it directly: "Does Transcend offer international shipping or service? Currently, we only serve within the 50 United States and the District of Columbia." Age is stated the same way: "Our services are only accessible to individuals aged 18 or over, or in some cases aged 21 or over. Our team of medical providers will assess your eligibility for treatment based on your age and objectives" — which is a real limit, honestly phrased, though the site never says which services carry the higher bar. The terms of conditions are narrower than the FAQ and say so: "Our Service is currently only available to individuals who are located in states in which we offer the Service", without naming the states. No clinician is named anywhere on the site, no licence number appears, and the pages that would carry that information — /pages/our-team and /pages/euvita-medical — are published and empty. Nothing here was verified against a state board.
Read on August 2026 from https://transcendcompany.com/pages/faq
Regulatory
The FDA warning letter
Checked, and none found
Assessment
What holds up, and what does not
- It names four pharmacies with street addresses and phone numbers in the terms of conditions, and states plainly that "your prescription(s) may be filled by and transferred between any of the Pharmacies".
- One page carries the sentence this category avoids, twice: "Compounded drug products are not FDA-approved. FDA does not evaluate compounded products for safety, effectiveness, or quality. Prescription products require an online consultation with a healthcare provider who will determine if a prescription is appropriate."
- It separates the platform from the practice of medicine in writing: "Transcend is not a healthcare provider", medical groups "employ or contract with physicians and allied health professionals", and "We do not control or interfere with the practice of medicine".
Show 5 more
- The rewritten weight-loss page uses the correct register for an unapproved molecule — "Tesofensine is currently being studied for its potential effects on appetite regulation. A licensed provider can assess whether it is appropriate for your health needs" — with no efficacy figure attached.
- Coverage and age limits are answered plainly rather than buried: "we only serve within the 50 United States and the District of Columbia", and services are 18+, "or in some cases aged 21 or over".
- Payment terms are unambiguous: "Transcend does not work with health insurers, but we do accept HSA and FSA as a method of payment. We can provide invoices and lab requisitions, but we don't offer procedure or diagnostic codes as we operate on a direct pay basis."
- Testimonials carry a real caveat rather than a decorative one: "Individual outcomes depend on various factors, including personal health conditions, adherence to treatment protocols, and lifestyle choices. No guarantees are made regarding specific results."
- It does not assert product testing it cannot document. There is no "tested for purity" badge anywhere on the site, which leaves nothing for a reader to discount.
- Two incompatible versions of the same claim are live at once. /pages/weight-loss hedges tesofensine and prints the compounded-drug disclaimer; /pages/semaglutide, linked from the treatment menu, still says "Peptides like semaglutide, tirzepatide, and tesofensine have shown potential in aiding weight loss".
- Tesofensine is not a peptide. It is a small-molecule triple monoamine reuptake inhibitor, originally developed as NS 2330 for Parkinson's and Alzheimer's disease, and the page calls it a peptide in the same sentence that describes its small-molecule mechanism.
- Tesofensine has no phase 3 anywhere. Thirteen studies are registered and the highest phase reached is 2; the largest obesity trial enrolled 200 people and finished in 2007. No product containing it has an FDA approval, and DailyMed returns zero labels.
Show 10 more
- The tesamorelin page says the molecule "has FDA approval for targeted fat reduction and metabolic improvement". The approval is for reduction of excess abdominal fat in HIV-infected adults with lipodystrophy, and the label's Limitations of Use says it "is not indicated for weight loss management as it has a weight neutral effect".
- That same page promises "Cognitive Enhancement" and "Lean Muscle Gain" as key benefits. The cognition evidence is in mild cognitive impairment, not enhancement in healthy adults; lean muscle gain is what Limitations of Use exists to deny.
- Six programmes are sold as peptide "stacks" and "trios" with no molecule named — Cognitive Clarity, Healing & Recovery, Immune Resilience, Skin Care, Men's Sexual Wellness and the Men's Vitality Bundle. "BPC-157", "TB-500", "CJC-1295", "sermorelin" and "ipamorelin" occur zero times across all 60 pages.
- Three published pages are blank. /pages/the-science, /pages/our-team and /pages/euvita-medical each render a headline and an empty content block, and all three sit in the sitemap. No clinician is named anywhere on the site.
- Epitalon is offered inside a skin-and-hair programme with the line "has been investigated in longevity research". A ClinicalTrials.gov search on 9 August 2026 returned zero studies for epitalon, zero for epithalon and zero for epithalamin — the molecule has never been registered as a trial intervention.
- GHK-Cu is offered on the same page. Its only registered trial opened for recruitment in February 2026, studies a topical gel on punch-biopsy wounds, and estimates completion in 2028. FDA names GHK-Cu for injectable routes on its safety-risk page; the site never says which route it dispenses.
- The regulatory category of what is sold is stated on exactly one page out of sixty. "503A" and "503B" occur zero times site-wide, and "compounding" appears only inside two pharmacies' company names.
- No medication price is published anywhere. The public product endpoint returns eight items — lab panels and supplements — of which five are marked unavailable, and the only purchasable clinical entry is a $199 starter package.
- No certificate of analysis exists for any lot, and no testing of any dispensed product is described: "certificate of analysis", "sterile", "potency" and "purity" occur zero times across the whole site.
- Disputes go to binding individual arbitration with a class-action waiver unless the customer opts out in time, and the waiver is extended to the medical groups and providers as third-party beneficiaries.
Verdict
The bottom line
Transcend is a company caught mid-edit, and the edit is going in the right direction. Somebody there has already written the two hardest sentences in this business — that compounded drug products are not FDA-approved and that FDA does not evaluate them for safety, effectiveness or quality; and that tesofensine "is currently being studied" rather than that it works. Both are on the weight-loss page today. One click away, the older pages are still selling: tesofensine as a peptide it is not, tesamorelin as holding an FDA approval for a use the label specifically excludes, and six programmes as peptide "stacks" and "trios" that name no peptide at all. The dispensing chain is disclosed better than almost anyone's — four pharmacies, four addresses, four phone numbers, and an explicit statement that your prescription may move between them — while the pages that would tell you who writes the prescription and on what evidence are published and blank. There is no price for any medication anywhere. The company is one editing pass away from being among the more honest operators reviewed here, and the pass has not finished.
Opens transcendcompany.com. A link is not a recommendation to take anything.
Two pages, one product, two different companies
Here is Transcend's weight-loss copy. Both quotations are live, both are in the published sitemap, and both are reachable from the same treatment menu.
From `/pages/weight-loss`:
Peptides like GLP-1 receptor agonists and Tesofensine have shown potential in aiding weight loss… Tesofensine is currently being studied for its potential effects on appetite regulation. A licensed provider can assess whether it is appropriate for your health needs.
Compounded drug products are not FDA-approved. FDA does not evaluate compounded products for safety, effectiveness, or quality.
From `/pages/semaglutide`:
Peptides like semaglutide, tirzepatide, and tesofensine have shown potential in aiding weight loss… Tesofensine is another peptide that works as a triple monoamine reuptake inhibitor. It enhances the levels of serotonin, dopamine, and norepinephrine in the brain, which can suppress appetite and promote weight loss.
The first is what a careful operator writes. The second states an efficacy mechanism as fact, carries no compounding disclaimer, and contains an error of classification that a peptide company should not make.
Tesofensine is not a peptide. It is a small molecule — a triple monoamine reuptake inhibitor, which is what the sentence itself says. It entered development as NS 2330, a Boehringer Ingelheim candidate for Parkinson's disease and Alzheimer's disease, and three of its registered trials are still filed under dementia. A peptide is a short chain of amino acids acting as a signalling molecule; a reuptake inhibitor is a different kind of object doing a different kind of job. If that distinction is unfamiliar, what a peptide actually is is the place to start — and it is the distinction Transcend's own skin page explains correctly two clicks away.
The evidence is the second problem:
Tesofensine in the registry, read 9 August 2026
| Trial | Phase | Population | Enrolled | Status |
|---|---|---|---|---|
| NCT00394667 | Phase 2 | Obesity | 200 | Completed 2007 |
| NCT00481104 | Phase 2 | Obesity, long-term safety | 140 | Completed |
| NCT02737891 | Phase 2 | Hypothalamic obesity (with metoprolol) | 60 | Completed |
| NCT00153010 | Phase 2 | Mild to moderate dementia | 430 | Completed |
| All 13 registered studies | Highest phase reached: 2 | — | — | No phase 3 exists |
Placing it in a list with semaglutide and tirzepatide — two molecules with completed phase 3 programmes and approved finished products — invites a reader to treat them as one class. They are not one class, and phase 2 is not a result.
Full analysis — 5 more sectionsThe approval that belongs to someone else's product · Six programmes, no molecules · The two molecules that are named, and the register they are named in · The pages that would answer the question are blank · What it adds up to
The approval that belongs to someone else's product
The tesamorelin page is the site's most confident, and it contains its clearest error.
Tesamorelin was developed through years of clinical research and has FDA approval for targeted fat reduction and metabolic improvement, with over a decade of data showing improved metabolism, body composition, and insulin sensitivity.
Two things are wrong in one sentence.
The indication has been deleted. The approved label reads: "EGRIFTA WR is indicated for the reduction of excess abdominal fat in HIV-infected adult patients with lipodystrophy." 2 Not "targeted fat reduction" in general. And directly beneath it, under Limitations of Use: "EGRIFTA WR is not indicated for weight loss management as it has a weight neutral effect."
There is no approval for "metabolic improvement" of any kind.
The approval belongs to a product, not a molecule. Transcend's four named pharmacies are compounders. The approval attaches to Theratechnologies' finished product — its application, its National Drug Code, its FDA-reviewed label — and does not travel to a compounded preparation of the same molecule. Transcend's own weight-loss page says so: "Compounded drug products are not FDA-approved." The two pages contradict each other, and the one that is right is the one that isn't selling tesamorelin. The compounded preparation is not the trial drug.
What the evidence does support is narrower and genuinely strong. A 412-patient randomised, double-blind, placebo-controlled phase 3 gave 2 mg of tesamorelin daily for 26 weeks; CT-measured visceral adipose tissue fell 15.2% on drug and rose 5.0% on placebo. 3 4 Every participant had HIV. Outside HIV the registry holds one phase 2 study of 60 people, completed January 2012. 5
Then the bullet list, which is where the page stops being about tesamorelin and starts being about how the reader would like to feel:
- Visceral fat reduction100percent
The trial's own result — in HIV-associated lipodystrophy
- Improved sleep quality40percent
Reported as a secondary measure in GHRH studies, not an approved use
- Cognitive enhancement25percent
Trials exist in mild cognitive impairment, not in healthy adults seeking enhancement
- Lean muscle gain5percent
The label's Limitations of Use denies a weight effect
The cognition claim is the one worth pinning down, because a trial does exist and it is not the trial the page implies. Registered work on GHRH and cognition is a 22-participant phase 1 at the University of Texas Medical Branch in adults with mild cognitive impairment 6, and a 151-participant phase 2 at the University of Washington in ageing and MCI. Both studied impairment. Neither studied enhancement in healthy adults, which is who is reading a page that promises to help you "perform, look, and feel the way you used to". The published trial in that programme is Baker et al., Archives of Neurology, 2012. 7
This is the recurring shape across the whole growth-hormone secretagogue family: a real result in a narrow population, resold as a general promise.
Six programmes, no molecules
Beyond the four molecules named above, Transcend's menu is built from stacks:
- Cognitive Clarity — "three physician-prescribed neuropeptides that work together to support memory, focus, mood stability and long-term performance"
- Healing & Recovery — "an advanced peptide and cartilage-support trio designed for faster recovery, inflammation reduction, joint restoration and connective-tissue health"
- Immune Resilience — "one of the most synergistic immune optimization trios available in clinical peptide and cellular medicine"
- Men's Sexual Wellness — "three compounds that work along different but complementary physiological and neurochemical pathways"
- Men's Vitality Bundle, Skin Care — the same construction
All 60 pages in the published sitemap were downloaded on 9 August 2026 and searched. The result:
0
0
0
0
6
Six molecules: tesamorelin, semaglutide, tirzepatide, tesofensine, GHK-Cu and epitalon. Not one of them is a nootropic, so whatever the three neuropeptides in Cognitive Clarity are, the site never says.
That is not a stylistic complaint. An unnamed drug cannot be looked up, cannot be checked for interactions, cannot be graded against a trial, and cannot be checked against FDA's published list of bulk substances a pharmacy may not lawfully compound from. 1 As a bound on the class this particular stack describes: the two molecules this market usually reaches for are semax and selank, a PubMed search restricted to randomised controlled trials returns three records for the pair — all in the Russian-language journal Zhurnal Nevrologii i Psikhiatrii, 2007 to 2015 — and FDA names both on that safety-risk page. 15
The two molecules that are named, and the register they are named in
The skin-and-hair page is written in a completely different voice from the tesamorelin page, and the difference is instructive.
GHK-Cu is a copper-binding peptide studied for its potential role in signaling pathways associated with collagen and skin structure.
Epitalon has been investigated in longevity research related to cellular aging pathways.
Neither sentence claims a result. That is a deliberate register — the structure-function hedge — and it is much harder to falsify than "has FDA approval for targeted fat reduction". It is also placed under the heading "How Peptide and Hormone Therapy Works for Better Skin and Hair", inside a programme a reader is being invited to buy, which is where the reach happens.
For GHK-Cu, the registry holds exactly one intervention trial: NCT07437586, a phase 2 split-wound study of a topical gel on standardised punch-biopsy wounds in healthy adults. It started recruiting on 2 February 2026 and estimates completion in March 2028. 13 It has reported nothing, and it is not a study of a systemic programme for skin appearance. FDA lists "GHK-Cu (for injectable routes of administration)" on its safety-risk page; the site never says which route it dispenses, and route changes the drug.
For epitalon, there is nothing at all. A ClinicalTrials.gov v2 intervention search on 9 August 2026 returned zero studies for "epitalon", zero for "epithalon" and zero for "epithalamin". 14 The molecule has never been registered as a trial intervention anywhere in the world, for any indication. DailyMed returns zero labels. The randomised literature a looser search surfaces tests epithalamin — a peptide extract of bovine pineal gland — which is not the synthetic tetrapeptide being dispensed.
So "investigated in longevity research" is a true sentence about cell and animal work, positioned where a reader will hear it as "tested in people". FDA's own entry for epitalon says the agency "has not identified safety-related information regarding epitalon for the proposed route of administration", which is the regulator saying it does not know. 1
The pages that would answer the question are blank
Transcend publishes three pages whose titles promise exactly what this review needs:
- 1 — Not reached
/pages/the-science
Renders an <h1> reading "The Science" and an empty content block. 923 bytes of <main>.
- 2 — Not reached
/pages/our-team
Renders "Our Team" and an empty content block. 920 bytes.
- 3 — Not reached
/pages/euvita-medical
Renders "eūvita Medical" — apparently the affiliated medical group — and an empty content block. 926 bytes.
All three are in the published pages sitemap. No clinician is named anywhere on the site; no licence number appears; no medical director is identified. The FAQ says a "team of medical providers" assesses eligibility, and the terms say medical groups "employ or contract with physicians and allied health professionals", but the page that would name one is empty.
Set against that, what Transcend does disclose is better than most:
Currently, the Pharmacies our Service utilizes for access to prescription fulfillment services are the following: AnazaoHealth [5710 Hoover Boulevard, Tampa, FL 33634]; Tailor Made Compounding [200 Moore Dr., Nicholasville, KY 40356]; Vios Compounding [31035 Schoolcraft Rd., Livonia, MI 48150]; Brooksville Rx [16140 Flight Path Dr., Brooksville, FL] … You agree and understand that your prescription(s) may be filled by and transferred between any of the Pharmacies.
Four companies, four addresses, four phone numbers, and an explicit statement that the prescription may move. Naming them is what let this review check them: AnazaoHealth Corporation holds a 2021 FDA warning letter concerning an outsourcing facility — addressed to a Las Vegas, Nevada site, not the Tampa address Transcend prints, so it belongs to the corporation at a different facility and nothing more is claimed from it. 16 The other three returned nothing.
What it adds up to
Transcend is not a company that does not know how to write honestly. It has already done it. The compounded-drug disclaimer, the hedged tesofensine sentence, the testimonial caveat, the pharmacy list, the plain statement that "Transcend is not a healthcare provider" — all of that is on the site today.
What is also on the site today is a page selling a compounded copy of an orphan HIV drug on the strength of an approval it does not have, a page calling a small molecule a peptide, six programmes named after outcomes rather than drugs, and three blank pages where the evidence, the clinicians and the medical group should be.
The gap between those two halves is not a difference of opinion about the science. It is the difference between the copy that has been through the rewrite and the copy that has not, and a reader clicking through the treatment menu cannot tell which one they have landed on. That is a claim outrunning its evidence with an unusual mitigating fact attached: the corrected version is already written, one URL away.
Questions
Frequently asked questions
Which peptides does Transcend sell?
Only six molecules are named anywhere on the site: tesamorelin, semaglutide, tirzepatide, tesofensine, GHK-Cu and epitalon. Everything else is sold as a stack — Cognitive Clarity is "three physician-prescribed neuropeptides", Healing & Recovery is "an advanced peptide and cartilage-support trio", Immune Resilience is an "immune optimization trio", and Men's Sexual Wellness "combines three compounds". All 60 pages in the published sitemap were downloaded on 9 August 2026 and searched: "BPC-157", "BPC 157", "TB-500", "CJC-1295", "sermorelin" and "ipamorelin" occur zero times. A drug that is not named cannot be looked up, cannot be checked for interactions, and cannot be graded against a trial.
Does Transcend say which pharmacy fills the prescription?
Yes. The terms of conditions name four with street addresses and telephone numbers: AnazaoHealth (5710 Hoover Boulevard, Tampa, FL 33634), Tailor Made Compounding (200 Moore Dr., Nicholasville, KY 40356), Vios Compounding (31035 Schoolcraft Rd., Livonia, MI 48150) and Brooksville Rx (16140 Flight Path Dr., Brooksville, FL). The same paragraph states that "your prescription(s) may be filled by and transferred between any of the Pharmacies". That is a real disclosure and it is treated as a pro here. On 9 August 2026 all four were screened against the live FDA warning-letter index: AnazaoHealth Corporation has a 2021 letter concerning an outsourcing facility, but that letter is addressed to a Las Vegas, Nevada site rather than the Tampa address Transcend prints, so it belongs to the corporation at a different facility. Tailor Made Compounding, Vios Compounding and Brooksville Rx each returned zero rows.
Is tesofensine a peptide?
No. Tesofensine is a small molecule — a triple monoamine reuptake inhibitor, which is what Transcend's own sentence describes even while calling it a peptide. It was developed as NS 2330, a Boehringer Ingelheim candidate for Parkinson's disease and Alzheimer's disease, and several of its registered trials are in dementia. On the evidence: thirteen tesofensine studies are registered on ClinicalTrials.gov and the highest phase reached is 2. The largest obesity trial, NCT00394667, enrolled 200 people and completed in 2007. No product containing tesofensine holds an FDA approval and a DailyMed query returns zero labels. Transcend's newer weight-loss page describes it correctly — "currently being studied for its potential effects on appetite regulation" — while the older semaglutide page does not.
Does tesamorelin have FDA approval for fat loss?
It has an approval, and not the one the page describes. Transcend says tesamorelin "has FDA approval for targeted fat reduction and metabolic improvement". The approved label reads: "EGRIFTA WR is indicated for the reduction of excess abdominal fat in HIV-infected adult patients with lipodystrophy", and under Limitations of Use, "EGRIFTA WR is not indicated for weight loss management as it has a weight neutral effect." There is no approval for metabolic improvement. The approval also attaches to a specific finished product from Theratechnologies; Transcend's four named pharmacies are compounders, and the site's own weight-loss page states that "Compounded drug products are not FDA-approved. FDA does not evaluate compounded products for safety, effectiveness, or quality." The phase 3 behind the real indication randomised 412 HIV patients and reported visceral fat falling 15.2% on drug against a 5.0% rise on placebo. Outside HIV, the registry holds one phase 2 study of 60 people, completed in January 2012.
Why does this review say Transcend's "Science" page is empty?
Because it is, and it was checked at the layer that matters. /pages/the-science, /pages/our-team and /pages/euvita-medical are all in Transcend's published pages sitemap. Requesting each of them and inspecting the served <main> element returns 923, 920 and 926 bytes respectively — in every case an <h1> carrying the page title and an empty content block beneath it. No paragraph, no citation, no clinician. The result is that no medical provider is named anywhere on the site, and neither is the affiliated medical group whose page exists to name it.
Is there evidence for epitalon?
No registered human evidence exists. On 9 August 2026 a ClinicalTrials.gov v2 intervention search returned zero studies for "epitalon", zero for "epithalon" and zero for "epithalamin" — the molecule has never been registered as a trial intervention anywhere in the world, for any indication — and a DailyMed query returns zero labels. The randomised literature that a looser search surfaces tests epithalamin, a peptide extract of bovine pineal gland, which is a different substance from the synthetic four-amino-acid peptide sold under the name epitalon. Transcend's sentence, "Epitalon has been investigated in longevity research related to cellular aging pathways", is true of laboratory work and does not claim a human result; it is graded as reaching past its evidence because of where it sits — inside a purchasable skin-and-hair programme. FDA names epitalon on its published page of bulk drug substances that may present significant safety risks, stating it "has not identified safety-related information regarding epitalon for the proposed route of administration".
Has Transcend received an FDA warning letter?
No. On 9 August 2026 the live FDA warning-letter index was queried for "transcend company", "transcendcompany", "transcend company inc", "transcend wellness", "transcend hrt", "transcend performance" and "euvita", with the returned row count compared to recordsFiltered on each query. Every one returned recordsFiltered=0 and zero rows. A bare query for "transcend" returned exactly one row — PolleyMed, LLC, dated 14 May 2026 — which is a different company; a letter is never filed against a business on a name resemblance. A positive control query for "skinnyrx" returned Lean Rx, Inc. dba SkinnyRx dated 20 February 2026 under the identical query shape, and the close-out column was validated separately against Belmar Pharma Solutions, Drug Depot, LLC., dba APS Pharmacy, whose 31 March 2023 letter carries a close-out date of 30 October 2023.
What does Transcend cost?
The clinical entry point is published and the medication is not. The storefront's public product endpoint returns eight items — lab panels and supplements, five of them marked unavailable — and the only purchasable clinical package is the $199 "Fast Track Starter Package with Guided Care", covering comprehensive lab testing if needed plus a wellness consultation and a personalised plan. No price for tesamorelin, semaglutide, tesofensine or any stack appears on any of the 60 pages. Transcend states that it "does not work with health insurers, but we do accept HSA and FSA as a method of payment", operates on a direct-pay basis, and provides invoices and lab requisitions but no procedure or diagnostic codes.
Does Transcend serve my state?
The FAQ says yes, everywhere: "Currently, we only serve within the 50 United States and the District of Columbia." The terms of conditions are narrower and do not resolve to a list — "Our Service is currently only available to individuals who are located in states in which we offer the Service" — without naming which those are. Services are restricted to people 18 or over, "or in some cases aged 21 or over", with the higher bar unexplained. No clinician licence is published anywhere on the site, and nothing here was verified against a state board.
Does Transcend publish testing or a certificate of analysis?
No, and it also does not claim to. Across all 60 pages downloaded on 9 August 2026, the strings "certificate of analysis", "third-party tested", "sterile", "potency", "purity" and "tested for" each occur zero times, and "USP" as a standard occurs zero times. There is no purity badge to discount and no laboratory named. The closest thing to a quality statement on the site is the disclaimer on the weight-loss page — "FDA does not evaluate compounded products for safety, effectiveness, or quality" — which describes what nobody has checked rather than asserting what Transcend has. Note that the site does describe extensive laboratory testing, but of the customer: a comprehensive panel through Quest with results in 7 to 10 business days. Diagnostics and product testing are different things.
Glossary
Key terms
Show definitions
- Structure-function register
- Wording that reports what a substance has been "studied for" or is "investigated in", rather than what it does. It is much harder to falsify than a claim of effect, and it can carry the same commercial weight when it appears inside a purchasable programme. Transcend's skin page is written entirely in it; its tesamorelin page is not.
- Limitations of Use
- A section of an FDA-approved label stating what a drug is specifically not indicated for. It is a boundary on the approval itself, not a caution. EGRIFTA WR's says the drug "is not indicated for weight loss management as it has a weight neutral effect".
- Triple monoamine reuptake inhibitor
- A small molecule that blocks the reuptake of serotonin, dopamine and norepinephrine. It is a pharmacological class of small molecules, not of peptides — which is why describing tesofensine as "another peptide that works as a triple monoamine reuptake inhibitor" is self-contradictory.
- Epithalamin vs epitalon
- Epithalamin is a peptide extract of bovine pineal gland; epitalon (also spelled epithalon) is a synthetic four-amino-acid peptide. The small randomised literature belongs to the first. The registry holds no trial of the second under any spelling, and it is the second that is dispensed.
- 503A compounding
- Preparation by a state-licensed pharmacy against a prescription for a named patient. Compounded preparations hold no FDA approval and FDA does not review them for safety, effectiveness or quality — a fact Transcend states correctly on one of its sixty pages.
- Certificate of analysis
- A lot-specific laboratory report stating what was tested and what the results were. Transcend publishes none — and, unusually for this category, also claims none, which leaves nothing for a reader to discount.
Method
How we checked this
Non-product facts last checked August 2026. Read the editorial policy for the rules this page is held to.
Read our methodology
Claims read first-party
Every quoted claim was read off Transcend's own pages on the date stamped against it, and the URL it came from is published beside it.
Trials read from the registry
Phase, status and enrolment come from ClinicalTrials.gov; identifiers and journals from PubMed's own records. Nothing here is cited from memory.
Absence claims bounded
Where we report that no trial exists, the page says what was searched, where, and when — never an unbounded claim that nobody has tested something.
Letters matched on full name
FDA letters are matched on the complete company name. A substring match would attach one firm's regulatory history to another with a similar name.
Sources
References
Show all 16 sources
- US Food and Drug Administration (2026). Certain Bulk Drug Substances for Use in Compounding that May Present Significant Safety Risks — content current as of 04/22/2026. Names epitalon, GHK-Cu (for injectable routes of administration), semax (heptapeptide) and selank acetate (TP-7), each with FDA's stated potential significant safety risk. Read 2026-08-09. fda.gov. https://www.fda.gov/drugs/human-drug-compounding/certain-bulk-drug-substances-use-compounding-may-present-significant-safety-risks
- Theratechnologies Inc. (2026). EGRIFTA WR (tesamorelin) for injection — prescribing information, Indications and Usage: "EGRIFTA WR is indicated for the reduction of excess abdominal fat in HIV-infected adult patients with lipodystrophy"; Limitations of Use: "EGRIFTA WR is not indicated for weight loss management as it has a weight neutral effect." Read 2026-08-09. DailyMed (US National Library of Medicine), SPL setid 839334d3-8c1d-4c26-9036-2ab524a6ea75. https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=839334d3-8c1d-4c26-9036-2ab524a6ea75
- Falutz J, Allas S, Blot K, et al. (2007). Metabolic effects of a growth hormone-releasing factor in patients with HIV. New England Journal of Medicine 357(23):2359-70 — visceral adipose tissue −15.2% on tesamorelin against +5.0% on placebo, 412 patients, 26 weeks. https://pubmed.ncbi.nlm.nih.gov/18057338/
- Theratechnologies (2026). TH9507 in Patients With HIV-Associated Lipodystrophy, NCT00123253 — phase 3, completed, enrolment 412 actual; conditions HIV infections and lipodystrophy. Read 2026-08-09. ClinicalTrials.gov (US National Library of Medicine). https://clinicaltrials.gov/study/NCT00123253
- Massachusetts General Hospital (2026). Effectiveness of Growth Hormone Releasing Hormone in Reducing Abdominal Fat in People Who Are Obese, NCT00675506 — official title "Physiologic Effects of Long-Term GHRH1-44 in Abdominal Obesity", phase 2, completed January 2012, enrolment 60 actual. Read 2026-08-09. ClinicalTrials.gov (US National Library of Medicine). https://clinicaltrials.gov/study/NCT00675506
- The University of Texas Medical Branch, Galveston (2026). The Effect of Growth Hormone Releasing Hormone on Cognitive Function in Individuals With Mild Cognitive Impairment, NCT02553603 — phase 1, completed 17 January 2019, enrolment 22 actual. Read 2026-08-09. ClinicalTrials.gov (US National Library of Medicine). https://clinicaltrials.gov/study/NCT02553603
- Baker LD, Barsness SM, Borson S, et al. (2012). Effects of growth hormone-releasing hormone on cognitive function in adults with mild cognitive impairment and healthy older adults: results of a controlled trial. Archives of Neurology 69(11):1420-9 — 20 weeks of GHRH; participants had mild cognitive impairment or were healthy older adults. https://pubmed.ncbi.nlm.nih.gov/22869065/
- NeuroSearch A/S (2026). Effect of Tesofensine on Weight Reduction in Patients With Obesity, NCT00394667 — "A Randomized, Double-blind, Placebo-controlled, Parallel-group, Multi-centre Study", phase 2, enrolment 200, completed September 2007. The largest registered obesity trial of the molecule. Read 2026-08-09. ClinicalTrials.gov (US National Library of Medicine). https://clinicaltrials.gov/study/NCT00394667
- US National Library of Medicine (2026). ClinicalTrials.gov v2 intervention search: "tesofensine" — 13 studies, of which the highest phase reached is PHASE2; no phase 3 of tesofensine is registered for any indication. A DailyMed query for tesofensine returns 0 labels. Run 2026-08-09. ClinicalTrials.gov (US National Library of Medicine). https://clinicaltrials.gov/search?intr=tesofensine
- Wilding JPH, Batterham RL, Calanna S, et al. (2021). Once-Weekly Semaglutide in Adults with Overweight or Obesity. New England Journal of Medicine 384(11):989-1002 — mean body-weight change −14.9% versus −2.4% on placebo at week 68. https://pubmed.ncbi.nlm.nih.gov/33567185/
- Novo Nordisk A/S (2026). STEP 1: Research Study Investigating How Well Semaglutide Works in People Suffering From Overweight or Obesity, NCT03548935 — phase 3, completed, enrolment 1,961 actual. Read 2026-08-09. ClinicalTrials.gov (US National Library of Medicine). https://clinicaltrials.gov/study/NCT03548935
- Eli Lilly and Company (2026). SURMOUNT-1: A Study of Tirzepatide (LY3298176) in Participants With Obesity or Overweight, NCT04184622 — phase 3, completed 6 July 2024, enrolment 2,539 actual. Read 2026-08-09. ClinicalTrials.gov (US National Library of Medicine). https://clinicaltrials.gov/study/NCT04184622
- Hudson Biotech (2026). Topical GHK-Cu Gel for Acute Skin Wound Healing, NCT07437586 — "A Phase 2, Randomized, Double-Blind, Vehicle-Controlled, Split-Wound Study of Topical GHK-Cu (Copper(II)-Peptide Complex) Gel to Accelerate Re-Epithelialization of Standardized Acute Skin Wounds in Healthy Adults." RECRUITING, target 60, started 2 February 2026, estimated completion 17 March 2028. The only registered GHK-Cu intervention trial. Read 2026-08-09. ClinicalTrials.gov (US National Library of Medicine). https://clinicaltrials.gov/study/NCT07437586
- US National Library of Medicine (2026). ClinicalTrials.gov v2 intervention searches: "epitalon" — 0 studies; "epithalon" — 0 studies; "epithalamin" — 0 studies. No registered trial of this molecule exists under any spelling, for any indication. A DailyMed query for epitalon returns 0 labels. Run 2026-08-09. ClinicalTrials.gov (US National Library of Medicine). https://clinicaltrials.gov/search?intr=epitalon
- US National Library of Medicine (2026). PubMed search: (semax[tiab] OR selank[tiab]) AND randomized controlled trial[pt] — 3 records, all published in Zhurnal Nevrologii i Psikhiatrii imeni S.S. Korsakova between 2007 and 2015. Run 2026-08-09. PubMed. https://pubmed.ncbi.nlm.nih.gov/?term=%28semax%5Btiab%5D+OR+selank%5Btiab%5D%29+AND+randomized+controlled+trial%5Bpt%5D
- US Food and Drug Administration, Division of Pharmaceutical Quality Operations IV (2021). Warning Letter to AnazaoHealth Corporation, 7465 W. Sunset Road, Suite 1200, Las Vegas, NV 89113 — MARCS-CMS 613214, 18 August 2021, concerning a facility registered as an outsourcing facility under section 503B. Note the address: this is a different facility from the Tampa, Florida location named in Transcend's terms of conditions, and the letter is attributed here to the corporation and that site only. Read 2026-08-09. fda.gov warning letter index. https://www.fda.gov/inspections-compliance-enforcement-and-criminal-investigations/warning-letters/anazaohealth-corporation-613214-08182021
Medical disclaimer: This content is for general educational purposes only and is not medical advice, diagnosis, or treatment. Always consult a licensed healthcare professional before starting, stopping, or changing any treatment.